Investor Relations


Advaxis, Inc. (NASDAQ: ADXS)

Advaxis is a clinical-stage biotechnology company focused on the development of immunotherapies to treat multiple different types of cancers. We are currently conducting clinical trials with our lead product candidate, axalimogene filolisbac (ADXS-HPV), in HPV-associated cervical cancer (late-stage trials), head and neck cancer (Phase 1/2) and anal cancer (Phase 1). Our second lead product candidate is ADXS-HER2, which we intend to develop for pediatric osteosarcoma and other HER2 overexpressing cancers, such as breast cancer. We intend to develop our third product candidate, ADXS-PSA, for prostate cancer, as well as to explore the potential to combine any of our proprietary immunotherapies in combination with other anticancer therapies. Advaxis has three commercial partnerships with other major biopharmaceutical companies for the development and commercialization of our proprietary cancer immunotherapies in countries outside the U.S. and for the global animal-health oncology market. Advaxis has created and is developing more than 20 distinct immunotherapies based on its proprietary Lm TechnologyTM, either directly or through strategic collaborations with recognized cancer centers of excellence.

[NOTE: Clinical trials of axalimogene filolisbac are on clinical hold as of Oct. 6, 2015.]

Recent News

Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program

Read More

Advaxis Presents New Data Featuring Its Lm Technology™ at the Society for Immunotherapy of Cancer 2015 Annual Meeting

Read More

Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference

Read More